PerkinElmer’s $5.25 Billion Acquisition of BioLegend

Wilmer Cutler Pickering Hale and Dorr advised PerkinElmer on the deal while Pillsbury Winthrop Shaw Pittman represented BioLegend.

PerkinElmer, a global leader committed to innovating for a healthier world, announced it has entered into an agreement to acquire BioLegend, a leading provider of life science antibodies and reagents, for $5.25 billion in a combination of cash and stock. The transaction will be the largest in PerkinElmer’s history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing conditions.

BioLegend provides its academic and biopharmaceutical customers with best-in-class antibodies and reagents in high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing, and has more than 700 employees with estimated 2022 revenues of $380 million. Upon joining PerkinElmer, BioLegend will expand PerkinElmer’s existing life science franchise into new segments, and its state-of-the-art campus in San Diego will become PerkinElmer’s global Center of Excellence for research reagent content development for the combined company.

The WilmerHale team advising PerkinElmer was led by Hal Leibowitz (Picture) with support from Andrew Bonnes, Jeffries Oliver-Li and Chris Gravallese on corporate and M&A matters. The team also included Steven Barrett on technology and licensing matters; Justin Ochs, Erika Robinson and Nathan Moore on financing matters; Amy Null and Scott Kilgore on benefits matters; Julie Hogan Rodgers, Bill Caporizzo, Meghan Walsh and Gavin Tullis on tax matters; and Barry Hurewitz on regulatory matters.

Involved fees earner: Richard Blaylock – Pillsbury Winthrop Shaw Pittman LLP; Nora Burke – Pillsbury Winthrop Shaw Pittman LLP; Hana Cho – Pillsbury Winthrop Shaw Pittman LLP; Alvin Dunn – Pillsbury Winthrop Shaw Pittman LLP; Joseph Fastiggi – Pillsbury Winthrop Shaw Pittman LLP; Nancy Fischer – Pillsbury Winthrop Shaw Pittman LLP; Mike Hird – Pillsbury Winthrop Shaw Pittman LLP; Laura Latham – Pillsbury Winthrop Shaw Pittman LLP; Gabriella Lombardi – Pillsbury Winthrop Shaw Pittman LLP; Michelle Mehok – Pillsbury Winthrop Shaw Pittman LLP; Kevin Meil – Pillsbury Winthrop Shaw Pittman LLP; Andrea Milano – Pillsbury Winthrop Shaw Pittman LLP; Jarrod Murphy – Pillsbury Winthrop Shaw Pittman LLP; Julie Park – Pillsbury Winthrop Shaw Pittman LLP; Matthew Rabinowitz – Pillsbury Winthrop Shaw Pittman LLP; Zachary Rozen – Pillsbury Winthrop Shaw Pittman LLP; Cindy Schlaefer – Pillsbury Winthrop Shaw Pittman LLP; Tara Shankar – Pillsbury Winthrop Shaw Pittman LLP; Joel Simon – Pillsbury Winthrop Shaw Pittman LLP; Evan Storm – Pillsbury Winthrop Shaw Pittman LLP; Paula Weber – Pillsbury Winthrop Shaw Pittman LLP; Steven Barrett – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Andrew Bonnes – WilmerHaleWilmer Cutler Pickering Hale and Dorr; William Caporizzo – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Christopher Gravallese – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Julie Hogan Rodgers – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Barry Hurewitz – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Scott Kilgore – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Hal Leibowitz – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Nathan Moore – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Amy Null – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Justin Ochs – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Jeffries Oliver-Li – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Erika Robinson – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Gavin Tullis – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Meghan Walsh – WilmerHaleWilmer Cutler Pickering Hale and Dorr;

Law Firms: Pillsbury Winthrop Shaw Pittman LLP; WilmerHaleWilmer Cutler Pickering Hale and Dorr;

Clients: BioLegend; PerkinElmer Inc.;

Author: Martina Bellini